Matching-adjusted indirect comparison of efficacy outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma

被引：0
|
作者：
Goldschmidt, H. [1 ]
Shah, N. [2 ]
Ayers, D. [3 ]
Davies, F. [4 ]
Cope, S. [3 ]
Mojebi, A. [3 ]
Dhanda, D. [5 ]
Hari, P. [6 ]
Patel, P. [5 ]
Huang, L. [5 ]
Hege, K. [5 ]
Dhanasiri, S. [7 ]
机构：
[1] Univ Hosp Heidelberg, Internal Med & Natl Ctr Tumor Dis NCT 5, Heidelberg, Germany
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] PRECISIONheor, Vancouver, BC, Canada
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Med Coll Wisconsin, Div Hematol & Oncol, Dept Med, Brookfield, WI USA
[7] Celgene Int Sarl, Boudry, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep256
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [1] A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
    Shah, Nina
    Ayers, Dieter
    Davies, Faith E.
    Cope, Shannon
    Mojebi, Ali
    Parikh, Kejal
    Dhanda, Devender
    Hari, Parameswaran
    Patel, Payal
    Huang, Liping
    Hege, Kristen
    Dhanasiri, Sujith
    BLOOD, 2020, 136
  • [2] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
    Anderson, Larry D., Jr.
    Munshi, Nikhil C.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
  • [4] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
    Einsele, H.
    Weisel, K.
    Goldschmidt, H.
    Munshi, N. C.
    Anderson, L. D., Jr.
    Shah, N.
    Jagannath, S.
    Berdeja, J.
    Lonial, S.
    Raje, N.
    Siegel, D. S.
    Lin, Y.
    Oriol, A.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
  • [5] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [6] Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial
    Delforge, Michel
    Shah, Nina
    Rodriguez-Otero, Paula
    Hari, Parameswaran
    Braverman, Julia
    Trigg, Andrew
    Patel, Payal
    Huang, Liping
    Hege, Kristen
    Dhanasiri, Sujith
    BLOOD, 2020, 136
  • [7] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [8] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna E.
    Rambaldi, Alessandro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
  • [9] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
    Shah, Nina
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Finney, Olivia
    Martin, Nathan
    Agarwal, Amit
    Rowe, Everton
    Campbe, Timothy B.
    San-Miguel, Jesus F.
    BLOOD, 2021, 138
  • [10] Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
    Rodriguez-Otero, Paula
    Ayers, Dieter
    Cope, Shannon
    Davies, Faith E.
    Delforge, Michel
    Mojebi, Ali
    Jansen, Jeroen P.
    Weisel, Katja
    Hege, Kristen
    Dhanasiri, Sujith
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2482 - 2491
12345